Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 182

1.

B cells as a therapeutic target for IFN-β in relapsing-remitting multiple sclerosis.

Ramgolam VS, Sha Y, Marcus KL, Choudhary N, Troiani L, Chopra M, Markovic-Plese S.

J Immunol. 2011 Apr 1;186(7):4518-26. doi: 10.4049/jimmunol.1000271. Epub 2011 Mar 2.

2.

IFN-beta1a inhibits the secretion of Th17-polarizing cytokines in human dendritic cells via TLR7 up-regulation.

Zhang X, Jin J, Tang Y, Speer D, Sujkowska D, Markovic-Plese S.

J Immunol. 2009 Mar 15;182(6):3928-36. doi: 10.4049/jimmunol.0802226.

3.

IFN-beta inhibits human Th17 cell differentiation.

Ramgolam VS, Sha Y, Jin J, Zhang X, Markovic-Plese S.

J Immunol. 2009 Oct 15;183(8):5418-27. doi: 10.4049/jimmunol.0803227. Epub 2009 Sep 25.

4.

Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis.

Mitsdoerffer M, Schreiner B, Kieseier BC, Neuhaus O, Dichgans J, Hartung HP, Weller M, Wiendl H.

J Neuroimmunol. 2005 Feb;159(1-2):155-64. Epub 2004 Dec 28.

PMID:
15652415
5.

Interferon beta inhibits the Th17 cell-mediated autoimmune response in patients with relapsing-remitting multiple sclerosis.

Zhang X, Markovic-Plese S.

Clin Neurol Neurosurg. 2010 Sep;112(7):641-5. doi: 10.1016/j.clineuro.2010.04.020. Epub 2010 Jun 1. Review.

PMID:
20570038
6.

Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis.

Hamamcioglu K, Reder AT.

Mult Scler. 2007 May;13(4):459-70. Epub 2007 Feb 9.

PMID:
17463069
7.

Simvastatin inhibits IFN regulatory factor 4 expression and Th17 cell differentiation in CD4+ T cells derived from patients with multiple sclerosis.

Zhang X, Tao Y, Troiani L, Markovic-Plese S.

J Immunol. 2011 Sep 15;187(6):3431-7. doi: 10.4049/jimmunol.1100580. Epub 2011 Aug 19.

8.

Interferon-beta inhibits Th17 cell differentiation in patients with multiple sclerosis.

Ramgolam VS, Markovic-Plese S.

Endocr Metab Immune Disord Drug Targets. 2010 Jun;10(2):161-7. Review.

PMID:
20384573
9.

Regulation of differentiation and functional properties of monocytes and monocyte-derived dendritic cells by interferon beta in multiple sclerosis.

Zang YC, Skinner SM, Robinson RR, Li S, Rivera VM, Hutton GJ, Zhang JZ.

Mult Scler. 2004 Oct;10(5):499-506.

PMID:
15471364
10.

Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression.

Krakauer M, Sorensen P, Khademi M, Olsson T, Sellebjerg F.

Mult Scler. 2008 Jun;14(5):622-30. doi: 10.1177/1352458507087136. Epub 2008 Apr 18.

PMID:
18424480
11.

Reduced production of noggin by immune cells of patients with relapsing-remitting multiple sclerosis.

Urshansky N, Mausner-Fainberg K, Auriel E, Regev K, Bornstein NM, Karni A.

J Neuroimmunol. 2011 Mar;232(1-2):171-8. doi: 10.1016/j.jneuroim.2010.10.007. Epub 2010 Nov 26.

PMID:
21111488
12.

IL-27 mediates the response to IFN-β therapy in multiple sclerosis patients by inhibiting Th17 cells.

Sweeney CM, Lonergan R, Basdeo SA, Kinsella K, Dungan LS, Higgins SC, Kelly PJ, Costelloe L, Tubridy N, Mills KH, Fletcher JM.

Brain Behav Immun. 2011 Aug;25(6):1170-81. doi: 10.1016/j.bbi.2011.03.007. Epub 2011 Mar 21.

PMID:
21420486
13.

Statins as immunomodulators: comparison with interferon-beta 1b in MS.

Neuhaus O, Strasser-Fuchs S, Fazekas F, Kieseier BC, Niederwieser G, Hartung HP, Archelos JJ.

Neurology. 2002 Oct 8;59(7):990-7.

PMID:
12370451
14.

Glatiramer acetate and IFN-beta act on dendritic cells in multiple sclerosis.

Hussien Y, Sanna A, Söderström M, Link H, Huang YM.

J Neuroimmunol. 2001 Dec 3;121(1-2):102-10.

PMID:
11730946
15.

Memory and naïve B-cell subsets in patients with multiple sclerosis.

Niino M, Hirotani M, Miyazaki Y, Sasaki H.

Neurosci Lett. 2009 Oct 16;464(1):74-8. doi: 10.1016/j.neulet.2009.08.010. Epub 2009 Aug 8.

PMID:
19666086
16.

Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients.

Rep MH, Schrijver HM, van Lopik T, Hintzen RQ, Roos MT, Adèr HJ, Polman CH, van Lier RA.

J Neuroimmunol. 1999 Apr 1;96(1):92-100.

PMID:
10227428
17.

Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis.

Brod SA, Marshall GD Jr, Henninger EM, Sriram S, Khan M, Wolinsky JS.

Neurology. 1996 Jun;46(6):1633-8.

PMID:
8649562
20.

Altered phenotype and function of blood dendritic cells in multiple sclerosis are modulated by IFN-beta and IL-10.

Huang YM, Stoyanova N, Jin YP, Teleshova N, Hussien Y, Xiao BG, Fredrikson S, Link H.

Clin Exp Immunol. 2001 May;124(2):306-14.

Items per page

Supplemental Content

Write to the Help Desk